Lihat Juga

• Milestone 44 - Updated review of HTA appraisal approaches for OMPs (WS1 of IMPACT HTA WP10)
  oleh: Elena Nicod, et al.
  Terbitan: (2020)
• D10.2 Guidance on Use of Patient Reported Outcome Measures in HTA Appraisals of Rare Disease Treatments
  oleh: Elena Nicod, et al.
  Terbitan: (2021)
• The Use of Patient‐Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
  oleh: Amanda Whittal, et al.
  Terbitan: (2020)
• HTA Appraisal Framework Suitable for Rare Disease Treatments
  oleh: Facey, K, et al.
  Terbitan: (2021)
• Guidance on use and implementation of outcomes-based managed entry agreements for rare disease treatments
  oleh: Facey, K, et al.
  Terbitan: (2021)